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Novelty and impact statement: 83 
Body fatness is now a well-established risk factor for colon cancer; however the potential 84 
mechanisms behind this relation are largely unknown. In a nested case-control study among 85 
662 incident colon cancer cases matched within risk-sets to 662 controls, the metabolic 86 
biomarkers, high-density lipoprotein cholesterol, non-high-molecular-weight adiponectin and 87 
soluble leptin receptor showed to be main mediators of adiposity-colon cancer association. If 88 
confirmed by future research, these findings may be implicated in the targeted prevention of 89 
colon cancer.   90 
 91 
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Abstract  112 
Adiposity is a risk factor for colon cancer, but underlying mechanisms are not well 113 
understood. We evaluated the extent to which eleven biomarkers with inflammatory and 114 
metabolic actions mediate the association of adiposity measures, waist circumference (WC) 115 
and body mass index (BMI), with colon cancer in men and women. We analysed data from a 116 
prospective nested case-control study among 662 incident colon cancer cases matched within 117 
risk-sets to 662 controls. Relative risks (RRs) and 95% confidence intervals (CIs) were 118 
calculated using conditional logistic regression. The percent effect change and corresponding 119 
CI-s were estimated after adjusting for biomarkers shown to be associated with colon cancer 120 
risk. After multivariable adjustment, WC was associated with colon cancer risk in men (top vs 121 
bottom tertile RR 1.68, 95% CI 1.06 - 2.65; Ptrend = 0.02) and in women (RR 1.67, 95% CI 122 
1.09 - 2.56; Ptrend = 0.03). BMI was associated with risk only in men. The association of WC 123 
with colon cancer was accounted mostly for by three biomarkers, high-density lipoprotein 124 
cholesterol, non-high-molecular-weight adiponectin and soluble leptin receptor, which in 125 
combination explained 46% (95% CI 37 to 57%) of the association in men and 50% (95% CI 126 
40 to 65%) of the association in women. Similar results were observed for the associations 127 
with BMI in men. These data suggests that alterations in levels of these metabolic biomarkers 128 
may represent a primary mechanism of action in the relation of adiposity with colon cancer. 129 
Further studies are warranted to determine whether altering their concentrations may reduce 130 
colon cancer risk. 131 
 132 
 133 
 134 
 135 
 136 
 137 
Introduction 138 
Adiposity is an established risk factor for colon cancer 1; however the underlying 139 
mechanisms are poorly understood. Various data, including results from large prospective 140 
studies such as the European Prospective Investigation into Cancer and Nutrition (EPIC), 141 
suggest that visceral adiposity and related metabolic abnormalities may play an important role 142 
in colon carcinogenesis 2. Thus, waist circumference (WC) - as a marker of abdominal fat 143 
accumulation - was equally strongly related to colon cancer risk in both sexes, whereas body 144 
mass index (BMI) - as a marker of general obesity - was related to risk of colon cancer among 145 
men but not among women, suggesting that WC may more accurately reflect the metabolic 146 
risk associated with cancer 3. Several circulating biomarkers of metabolic processes were 147 
shown to be associated with colon cancer risk, including C-peptide as a marker of 148 
hyperinsulinemia 4, glycated hemoglobin (HbA1c) as a marker of hyperglycemia 5, high-149 
density lipoprotein cholesterol (HDL-C) as a marker of dyslipidemia 6, high sensitivity C-150 
reactive protein (CRP-hs) as a marker of chronic low grade inflammation 7, and reactive 151 
oxygen metabolites (ROM) reflecting  oxidative stress 8. Insulin may also be involved in 152 
colorectal carcinogenesis through insulin-like growth factor 1 (IGF-1) acting as potent 153 
mitogen; although evidence on the association of circulating IGF-1 levels with colon cancer 154 
risk has not been convincing 9. Visceral adipose tissue is metabolically more active compared 155 
to subcutaneous fat, secreting a variety of cytokines and hormones (adipokines), thereby 156 
highlighting the role of adipose tissue in regulating energy balance and potentially also in 157 
affecting angiogenesis and tumor growth 10, 11. Thus, recent EPIC findings suggested an 158 
important role of soluble leptin receptor (sOB-R) 12 and non-high-molecular-weight (HMW) 159 
adiponectin in colon cancer risk 13. However, it remains to be answered to what extent these 160 
metabolic biomarkers may explain the association of adiposity with colon cancer. It is also 161 
unclear to what extent the role of these potential mediating biomarkers differs between men 162 
and women given the known differences in body shape and fat accumulation between sexes. 163 
Therefore, we aimed to investigate to what extent the association between adiposity, as 164 
measured by WC and BMI, with colon cancer risk in the EPIC cohort may be mediated by 165 
metabolic biomarkers shown to be related with colon cancer risk.   166 
Material and methods 167 
Study population 168 
EPIC is a large prospective study with approximately 520 000 participants, aged 25 to 169 
70 years at enrollment during the period from 1992 through 2000 and recruited from 23 170 
centers in 10 European countries [Denmark, France, Germany, Greece, Italy, the Netherlands, 171 
Norway, Spain, Sweden, and the United Kingdom]14. Participants gave written informed 172 
consent, underwent anthropometric measurements, and completed questionnaires on socio-173 
demographic and lifestyle characteristics, including detailed dietary assessment14. Blood 174 
samples were collected from about 65% of the women and 93% of the men using standardized 175 
protocols14. The participants’ body weight and WC were mostly measured with the exception 176 
of EPIC-Oxford center where weight and WC were derived from prediction equations based 177 
on self-reports of all participants and measurements in a subsample of the Oxford cohort 15.  178 
Cohort follow-up and case ascertainment 179 
Incident cancer cases were identified through record linkage with regional cancer 180 
registries or using a combination of methods, including health insurance records, cancer and 181 
pathology registries, and active follow-up through study subjects and their next-of-kin. 182 
Closure dates for the present study were defined as the latest date of complete follow-up for 183 
both cancer incidence and vital status, and ranged from December 1999 to June 2003 for 184 
centers using registry data, and from June 2000 to December 2002 for centers using active 185 
follow-up procedures. For the present study, colon cancers were defined as tumors in the 186 
cecum, appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, and 187 
descending and sigmoid colon (C18.0-C18.7, according to the 10th Revision of the 188 
International Statistical Classification of Diseases, Injury and Causes of Death), as well as 189 
tumors that were overlapping or unspecified (C18.8 and C18.9).  190 
Nested case-control study 191 
A total of 662 incident cases of colon cancer (292 men, 370 women) were included in 192 
the present analyses. An incidence density sampling protocol was used such that for each case 193 
one control subject was chosen at random among appropriate risk sets consisting of all cohort 194 
members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis 195 
of the index case. Matching characteristics were study center, sex, age, time of blood 196 
collection, and fasting status. Women were also matched on menopausal status. 197 
Premenopausal women were matched on phase of the menstrual cycle at blood collection, and 198 
postmenopausal women were matched on current use of hormone replacement therapy.  199 
Exclusion criteria and management of missing data  200 
Excluded from the analysis were the subjects from Norway and the Malmö center in 201 
Sweden which did not provide blood samples for the current study, as well as subjects with 202 
missing information on anthropometric  measurements (n=132). Data for the measurements of 203 
several biomarkers was missing in cases and controls as follows: IGF1 (67/217); ROM (4/3); 204 
TG (9/5); HDL-C (3/1); C-peptide (94/231), Hba1c (118/254); CRP-hs (31/40). Overall, 205 
participants with missing information on biomarkers tended to be slightly more educated 206 
(Supplementary Table 1). No substantial differences were seen in the other characteristics, 207 
except for that male cases with missing values were less likely to be physically inactive, but 208 
consumed more alcohol and red meat compared with all participants. However, these were 209 
only 37 cases and in sensitivity analysis excluding these participants did not substantially 210 
change risk estimates (data not shown). Under the assumption that values are missing at 211 
random and after proving that the pattern of missing data was arbitrary, we applied multiple 212 
imputation technique 16. All variables in the regression model were included in the procedure. 213 
Ten duplicate datasets were sampled from their predictive distribution based on the observed 214 
data with the missing values replaced by imputed values.  215 
Laboratory Procedures 216 
Blood samples were processed, aliquotted into heat-sealed straws, and stored in liquid 217 
nitrogen freezers (-196°C) 14. Storage protocols differed in Denmark and Sweden, where tubes 218 
were stored in the vapour phase of liquid nitrogen (-150 °C) or in -80°C freezers, respectively. 219 
The blood collection and processing protocols are described in detail elsewhere 17. Approval 220 
was obtained from the ethics review board of the International Agency for Research on 221 
Cancer, Lyon, France and the local review boards. The measurement of all biomarkers 222 
included in the analysis, C-peptide 4, HbA1c 5, TG, HDL-C 6, CRP-hs 7, IGF-1 9, ROM 8, 223 
adiponectin, non-HMW-adiponectin 13, and sOB-R 12 has been described elsewhere.  224 
Statistical methods 225 
Spearman partial correlation coefficients, adjusted for age at study recruitment and case-226 
control status were estimated to assess the correlations between baseline WC or BMI and 227 
biomarkers; as well as among the biomarkers. Conditional logistic regression was used to 228 
assess the association of WC and BMI with colon cancer. Relative risks (RRs), estimated 229 
from odds ratios as derived from the risk set sampling design 18 and 95% confidence intervals 230 
(CI-s) were computed. The multivariable model included possible confounders other than 231 
those controlled for by matching: smoking status, education, alcohol, and physical activity. 232 
Further adjustment for dietary factors (fish and shellfish, red and processed meat, fibre, fruits 233 
and vegetables) did not change the risk estimates, therefore we have not included these 234 
variables in the final multivariable model. Data was analysed according to tertiles based on 235 
the distribution of WC or BMI among controls and P-values for linear trends across tertiles 236 
were calculated using the median levels of WC or BMI as a metric variable. For the mediation 237 
analysis, we selected biomarkers according to the criteria of Baron and Kenny, 1986 19, 20; in 238 
short, these were biomarkers related to adiposity measures and shown in EPIC to be 239 
independently associated with colon cancer risk. To explore potential mediation effect, we 240 
first added each individual biomarker to the multivariable-adjusted model and examined the 241 
relative change in the risk estimates across tertiles as well as changes in the linear trends. 242 
Second, we explored the associations continuously per unit increase in WC or BMI and 243 
estimated the percent of effect change in regression coefficients (β-s) after the multivariable 244 
model was additionally adjusted for each of the individual biomarkers using the difference of 245 
coefficients method. This method was originally proposed by Freedman and Schatzkin, 1992 246 
21, 22 and further adapted for Cox regression models by Lin, Fleming and De Gruttola, 1997 23. 247 
The corresponding 95% confidence intervals (CI) were calculated based on Fieller’s theorem 248 
24. Finally, to test the significance of mediation effect, we applied the Sobel’s test 25, 26. In 249 
sensitivity analyses, we repeated the main multivariable adjusted analysis after excluding 250 
cases diagnosed in the first 2 years of follow up (n=173); we also repeated the analysis for 251 
markers that may be influenced by fasting status, such as C-peptide, after excluding non-252 
fasting participants (n = 642).  253 
Two-sided P-values of less than 0.05 were considered to indicate statistical 254 
significance. All statistical analyses were performed using SAS Enterprise Guide, Version 4.3 255 
(SAS Institute, Inc., Cary, North Carolina, USA). 256 
Results 257 
The baseline characteristics of incident colon cancer cases and their corresponding controls in 258 
men and women are presented in Table 1. Overall, cases of colon cancer had higher 259 
concentrations of C-peptide, CRP-hs and ROM, and lower concentrations of non-HMW 260 
adiponectin and sOB-R compared to controls. WC and BMI were highly correlated with each 261 
other in both men (r = 0.84) and women (r = 0.83).  262 
All biomarkers were correlated with both WC and BMI with the exception of IGF-1 263 
(Table 2). The associations among the different biomarkers were in the expected direction and 264 
ranged from weak to moderate strength (Table 3). Of note, since IGF-1 was not correlated to 265 
obesity measures, it did not fulfill the requirements of being a potential mediating variable; 266 
therefore we did not include it in subsequent mediation analyses.  267 
In multivariable adjusted logistic regression, WC was associated with risk of colon 268 
cancer in both men and women (top vs bottom tertile, RR 1.68, 95% CI 1.06 - 2.65, ; Ptrend = 269 
0.02 in men; RR 1.67, 95% CI 1.09 - 2.56, Ptrend = 0.03 in women; Table 4). In subsequent 270 
analyses, we assessed the association of colon cancer with WC continuously per 10 cm 271 
increase and estimated the percent change in regression coefficients after adjustment for each 272 
biomarker (Table 5). sOB-R, non-HMW-adiponectin and HDL-C were the three biomarkers 273 
that explained to the greatest extent the association individually and in combination explained 274 
46% (95% CI 37 to 57%) of the association in men and 50% (95% CI  40 to 65%) of the 275 
association in women (Table 5). Factors that differentially explained the association by sex 276 
were ROM, which accounted for 21% (95% CI 16 to 26%) of the association in men and 8% 277 
(95% CI 9 to 12%) of the association in women; as well as C-peptide, accounting for 30% 278 
(95% CI 22 to 40%) of the association in women and -9% (95% CI -14 to -4%) of the 279 
association in men. When we included ROM (as a biomarker more strongly explaining the 280 
association in men compared to women) in combination with the three most important 281 
biomarkers (sOB-R, non-HMW adiponectin and HDL-C), the percent change in risk was 71% 282 
(95% CI 58 to 86%) in men and 58% (95% CI 47 to 75%) in women; when instead we 283 
included C-peptide (as a biomarker more strongly explaining the association in women 284 
compared to men) in the same model, the respective values were 33% (95% CI 24 to 44%) in 285 
men and 53% (95% CI 40 to 68%) in women (Table 5). The results from the Sobel’s test 286 
further confirmed that the association between WC and colon cancer was statistically 287 
significantly mediated by sOB-R, non-HMW adiponectin and HDL-C (Supplementary Table 288 
2).  289 
BMI was statistically significantly associated with risk of colon cancer only in men 290 
(top vs bottom tertile, RR 1.33, 95% CI 0.85 - 2.07, Ptrend = 0 04), but not in women (RR 1.21, 291 
95% CI 0.76 - 1.78, Ptrend = 0.34)). In men, the highest percent change in β coefficients was 292 
observed after the multivariable model for BMI (continuously per 5 units increase) was 293 
further adjusted for a sOB-R, HDL-C, non-HMW adiponectin and ROM, which in 294 
combination explained 90% (95% CI 85 to 132%) of the association (Supplementary Table 3). 295 
No substantial differences in risk estimates were observed after excluding people diagnosed 296 
with cancer during the first two years of follow-up, or non-fasting participants (for C-peptide) 297 
(data not shown). 298 
Discussion 299 
In this nested case-control study, the three biomarkers that explained the largest 300 
proportion of the association of adiposity with colon cancer risk were HDL-C, non-HMW 301 
adiponectin and sOB-R. Factors that differentially explained the association in men and 302 
women were ROM and C-peptide. These findings support the hypothesis that pathways 303 
reflected by these biomarkers maybe responsible for mediating the effects of adiposity on 304 
colon cancer risk.  305 
As shown previously in EPIC 3, in our analysis, WC was associated with colon cancer 306 
risk in men and in women; whereas BMI showed an association only among men. Since WC 307 
is more strongly related to abdominal fat accumulation than BMI, these findings suggest that 308 
it is particularly visceral fat that may increase colon cancer risk. Thus, more precise 309 
characterization of the risk-defining obesity phenotype may be achieved in a simple way by 310 
measuring WC in addition to BMI, but also by using metabolic biomarkers. 311 
In our data, non-HMW adiponectin and sOB-R, accounted for the largest proportion of 312 
the adiposity-colon cancer association. Adiponectin, the most abundant protein secreted by 313 
adipose tissue, exerts insulin-sensitizing, anti-inflammatory, anti-atherogenic, pro-apoptotic, 314 
and anti-proliferative properties 27.  In contrast to other adipokines, adiponectin is inversely 315 
related to obesity and metabolic alterations 28. It circulates in plasma as a trimer, a hexamer 316 
and a high-molecular weight (HMW) form, and experimental evidence suggests that HMW 317 
and non-HMW adiponectin fractions may have different biologic activities, such that the 318 
HMW form may be more closely related to insulin sensitivity, whereas complexes with lower 319 
molecular weight (i.e. non-HMW adiponectin) were suggested to have an anti-inflammatory 320 
potential 29. Recently, EPIC data suggested an important role of the non-HMW adiponectin 321 
fraction in colon cancer risk 13. In this study, circulating pre-diagnostic concentrations of total 322 
adiponectin and non-HMW-adiponectin were inversely associated with risk of CRC, 323 
independent of dietary and lifestyle factors. In contrast, HMW-adiponectin concentrations 324 
were not statistically significantly related to CRC 13. In humans, serum sOB-R was suggested 325 
as a marker reflecting the impairment of leptin action in type 2 diabetes 30 and was inversely 326 
associated with obesity 31 and insulin resistance 32, 33. EPIC data further suggest that sOB-R 327 
may play an important role in the development of CRC 12. We observed that this protein was 328 
strongly inversely associated with colon cancer risk, independent of adiposity measures, 329 
baseline leptin concentrations and metabolic biomarkers 12. Leptin concentrations were not 330 
associated with colon cancer risk in this study population 12. These data collectively implies 331 
that adipokines, merely considered as markers of body fatness, may represent quite more 332 
complex and strong pathogenic actions in colon carcinogenesis.  333 
Our results further suggest that HDL-C may also potentially mediate the association 334 
between adiposity and colon cancer. The question whether HDL-C may act as a secondary 335 
epiphenomenon, i.e. reflecting impaired metabolic health, or is causally related to cancer is, 336 
yet to be answered. In the EPIC data, HDL-C was associated with risk of colon cancer even 337 
after accounting for metabolic syndrome, arguing against its role as simple epiphenomenon6. 338 
Although HDL-C is implicated in overall cancer risk in large cohort studies34 and randomized 339 
control trials35, biological mechanisms that might account for a HDL-C–cancer relationship 340 
are not well understood. On one side, low HDL-C may indirectly influence carcinogenesis, by 341 
reflecting chronic conditions that increase inflammation and insulin resistance 36. On the other 342 
side, HDL-C may exert direct cancer-protective effects by regulation of apoptosis 37 and 343 
cellular proliferation required for cancer growth and metastasis38. For example, HDL 344 
mimetics were demonstrated to inhibit tumor growth and development in mouse models of 345 
colon cancer38. In addition, HDL-cholesterol exerts direct anti-oxidant, immune-protective 346 
and anti-inflammatory properties that may be relevant for colon cancer36,39,40,41. In the largest 347 
to date prospective study on blood lipids and CRC risk within EPIC, HDL-C was 348 
independently associated with CRC even after controlling for biomarkers of systemic 349 
inflammation, insulin resistance and oxidative stress 6. Interestingly, apart from established 350 
pathways, recent evidence suggest that HDL-C may also decrease white adipose tissue mass, 351 
increase energy expenditure, and promote the production of adipose-derived cytokines, such 352 
as adiponectin42. Nevertheless, use of lipid lowering drugs, statins, in persons without cancer, 353 
does not influence cancer incidence and cancer-related mortality43. However, evidence is 354 
based on trials with relatively short trial period of approximately 5 years to find a protective 355 
effect on invasive cancers. Further,  most trials have been focused mostly on effects related to 356 
reducing LDL cholesterol, and not on elevating HDL-cholesterol, that may be more important 357 
for cancer risk. Further work on the various mechanisms of HDL-C action is warranted for 358 
revealing new prophylactic strategies with potential relevance to cancer prevention.  359 
Our findings further suggest that the extent to which some biomarkers may mediate 360 
the association between WC and colon cancer differ in men and in women. Thus, higher 361 
proportion of the association between WC and colon cancer was explained by ROM in men, 362 
while by C-peptide in women. It is not clear why ROM may mediate the association between 363 
abdominal adiposity and colon cancer in men but not in women. On one side, it may be 364 
possible that this is due to the stronger correlation between ROM and WC in men than in 365 
women in our data. On the other side, determinants of oxidative stress may be differentially 366 
distributed in men and in women and thus influence the results. C-peptide, a marker for 367 
insulin secretion that has a longer half-life than insulin, was consistently associated with risk 368 
of colon cancer in a number of epidemiological studies 44, 45 including EPIC 4, though no 369 
statistical heterogeneity of the results by gender was reported. It maybe speculated that WC in 370 
women may be more closely related to insulin resistance state compared to men, which may 371 
explain why C-peptide may mediate the association of WC with colon cancer in women but 372 
not in men.  373 
Our data do not support the hypothesis that circulating IGF-1 levels may mediate the 374 
association of adiposity with colon cancer risk. Adiposity measures were inversely though 375 
non-significantly associated with IGF-1 concentrations, thus making IGF-1 to fall beyond the 376 
statistical requirement for a potential mediating variable. Similar inverse associations, that 377 
were also statistically significant, have been reported in the National Health and Nutrition 378 
Examination Survey (NHANES) III 46. Furthermore, in EPIC IGF-1 was not related to 379 
colorectal cancer and a recent meta-analysis of 9 prospective cohort studies suggested only a 380 
modest role for elevated circulating IGF-I levels in the development of colorectal cancer 9.  381 
 Strengths of our study include the prospective design, the measured rather than self-382 
reported WC and BMI (from majority of EPIC centers), exploration of a wide range of 383 
biomarkers, including novel adipokines, and the detailed information on a number of dietary 384 
and lifestyle factors, that were  used to control the analyses. Some limitations of the current 385 
study should also be considered. A single assessment of biomarker concentrations at baseline 386 
may be susceptible to short-term variation, which could lead to “bias toward the null”. 387 
However, previously, most of the biomarkers indicated high reliability of single 388 
measurements over time47. We used C-peptide and HbA1c as long-term markers for insulin 389 
and glucose concentrations 48. Nevertheless, the adjustment for a single measurement or the 390 
use of surrogate markers in our analysis may not have sufficiently represented the effects of 391 
hyperinsulinemia and hyperglycemia. In our study data was missing on a number of 392 
biomarkers, however no differences were seen between participants with and without data on 393 
key variables with respect to population characteristics. Furthermore, to account for missing 394 
values we have applied  multiple imputation method considered as the most efficient missing 395 
data method in molecular epidemiology studies49. In the present study, only a subset of 396 
subjects was fasting at the time of blood draw. The fasting status may be important in 397 
differentiating effects of chronically elevated blood insulin levels (i.e. higher fasting serum C-398 
peptide levels) and postprandially elevated blood insulin levels (i.e. higher nonfasting serum 399 
C-peptide levels). However, previously no statistically significant heterogeneity in the 400 
association of C-peptide and colon cancer by fasting status was observed4. In our data we 401 
have conducted the analysis for C-peptide after excluding non-fasting participants and results 402 
were not considerably changed. Further, some biomarkers that were studied in the analysis as 403 
potential mediators are interrelated with each other. Thus, by adjusting for one biomarker, we 404 
may also partially account for the effect of one or more other related biomarkers. Finally, it 405 
should be noted that the mediators of the association between adiposity and colon cancer may 406 
be simply statistical intermediates and markers of various pathogenic processes, but not on the 407 
causal pathway to colon cancer50.   408 
In summary, these data suggest HDL-C, non-HMW adiponectin and sOB-R to be the 409 
three biomarkers mediating to the greatest extent the association between adiposity and colon 410 
cancer. While alterations in the levels of these metabolic biomarkers may represent a primary 411 
mechanism of action in the relation of adiposity with colon cancer, they may also point to 412 
targets for prevention of obesity-induced colon cancer. Further studies are warranted to 413 
determine whether altering the concentrations of these metabolic biomarkers reduces colon 414 
cancer risk.   415 
 416 
 417 
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Table 1 Baseline characteristicsa of colon cancer cases and controls, the European Prospective Investigation into Cancer and Nutrition Cohort (1992-2003) 
Variable 
Men Women 
Cases (n=292) Controls (n=292) Cases (n=370) Controls (n=370) 
Age, years, mean ± SD 59.3±6.9 59.3±6.9 58.6±7.5 58.6±7.5 
University degree, % 21.6 24.3 14.0 13.2 
Physically inactive, % 17.8 14.7 12.7 9.7 
Smokers, % 28.1 25.3 20.0 17.0 
Alcohol intake, g/day 15.8 (6.4-36.6) 12.1 (5.6-32.2) 3.2 (0.4-12.4) 4.4 (0.5-12.1) 
Dietary factors     
Fibre, g/day, median (IQR) 22.4 (17.4-28.3) 23.6 (19.2-29.7) 22.1(17.3-27.2) 22.1 (17.8-26.1) 
Fruits and vegetables, g/day, median (IQR) 336.8 (217.7-492.1) 361.5 (229.3-526.4) 428.8 (284.5-574-7) 446.4 (295.3-583.5) 
Red and processed meat, g/day, median (IQR) 99.2 (64.6-134.1) 93.7 (55.1-130.1) 69.9 (42.0-98.4) 70.3 (45.1-95.8) 
Fish and shellfish, g/day, median (IQR) 29.4 (16.7 -52.5) 32.5 (18.2-56.9) 24.3 (11.1-40.9) 26.6 (12.8-49.8) 
Anthropometric factors     
Body mass index, kg/m2, mean ± SD 27.3±4.0 26.5±3.4 26.4±4.8 26.1±4.3 
Waist circumference, cm, mean ± SD 97.8±10.6 94.8 ±9.5 84.3±12.1 82.6±11.2 
Waist to hip ratio, mean ± SD 0.96±0.1 0.94±0.06 0.81±0.8 0.81±0.07 
Biomarkers     
Adiponectin,  µg/mL, median (IQR) 5.4 (3.9-7.0) 5.3 (4.1-7.2) 8.3 (6.2-10.8) 8.4 (6.3-10.8) 
HMW-adiponectin,  µg/mL, median (IQR) 2.5 (1.5-3.7) 2.5 (1.7-3.7) 4.6 (3.2-6.7) 4.5 (3.1-6.4) 
Non-HMW adiponectin,  µg/mL, median (IQR) 2.7 (2.2-3.5) 3.0 (2.5-3.6) 3.6 (2.8-4.5) 3.9 (3.0-4.7) 
sOB-R, ng/mL, median (IQR) 21.0 (17.3-24.3) 22.0 (18.3-26.8) 19.8 (15.5-24.2) 21.0 (16.9-26.2) 
CRP-hs, mg/L, median (IQR) 2.8 (1.2-5.0) 1.9 (0.9-3.9) 3.3 (1.2-5.7) 2.7 (1.2-5.3) 
HbA1c , %, median (IQR) 5.8 (5.5-6.1) 5.7 (5.4-6.1) 5.8 (5.5-6.1) 5.7 (5.4-6.1) 
C-peptide, ng/mL, median (IQR) 4.4 (3.2-6.6) 4.3 (3.0-6.6) 3.7 (2.7-5.4) 3.5 (2.5-5.5) 
HDL-cholesterol, mmol/l, median  (IQR)  1.2 (1.0-1.5) 1.3 (1.1-1.6) 1.5 (1.3-1.8) 1.5 (1.3-1.9) 
Triglycerides, mmol/l,  median (IQR) 1.7 (1.1-2.4) 1.5 (1.0-2.2) 1.3 (1.0-2.0) 1.3 (0.9-2.0) 
IGF-1, ng/mL,  median (IQR) 217.8 (179.0-258.4) 214.2 (170.7-261.2) 200.1 (155.9-247.2) 196.9 (155.2-249.6) 
ROM, U/ml,  median (IQR) 376.5 (334.5-418.0) 352.0 (317.0-396.0) 423.0 (385.0-472.0) 409.0 (371.0-453.0) 
 
 
aAdjusted for age at recruitment and case-control status. 
b Weight (kg)/height (m)2. 
cP-value > 0.05.  
Note: All P values are statistically significant (P<.005) except for the marked instances. 
HbA1c = glycated hemoglobin; IGF-1= insulin growth factor 1; HDL-cholesterol = high-density-lipoprotein cholesterol; CRP-hs = high-sensitivity C-reactive protein; ROM= 
reactive oxygen metabolites; HMW-adiponectin = high-molecular-weight adiponectin; sOB-R = soluble leptin receptor. 
 
Table 2 Spearman partial correlationsa of waist circumference and body mass indexb with biomarkers in controls (n=662), the European 
Prospective Investigation into Cancer and Nutrition Cohort (1992-2003) 
 Waist circumference Body mass index 
 Men Women Men Women  
Waist circumference - - 0.84 0.84 
Adiponectin -0.22 -0.35 -0.22 -0.22 
HMW-adiponectin -0.20 -0.33 -0.21 -0.21 
Non-HMW adiponectin -0.20 -0.29 -0.20 -0.20 
sOB-R -0.36 -0.42 -0.37 -0.37 
CRP-hs 0.31 0.30 0.23 0.31 
HbA1c  0.22 0.23 0.21 0.19 
C-peptide 0.31 0.33 0.30 0.28 
HDL-cholesterol -0.22 -0.29 -0.24 -0.24 
Triglycerides 0.28 0.30 0.26 0.26 
IGF-1 -0.02c -0.07 -0.02c -0.02c 
ROM 0.16 0.10 0.14 0.14 
 aAdjusted for sex and age at study recruitment.  
bP values in parentheses. 
HbA1c; = glycated hemoglobin; HDL-cholesterol =high-density-lipoprotein cholesterol; CRP-hs = high-sensitivity C-reactive protein; ROM = reactive oxygen metabolites; HMW-
adiponectin = high-molecular-weight adiponectin; sOB-R = soluble leptin receptor. 
Table 3 Spearman partial correlationsa among biomarkers in controls (n=662)b, the European Prospective Investigation into Cancer and Nutrition  Cohort (1992-
2003)  
 Adiponectin HMW-
adiponectin 
Non-HMW-
adiponectin 
sOB-R CRP-hs HbA1c C-peptide TG HDL-C IGF-1 ROM 
Adiponectin 1.00  
 
0.96 
(<.0001) 
0.85 
(<.0001) 
0.31 
(<.0001) 
-0.16 
(<.0001) 
-0.12 
(<.0001) 
-0.20 
(<.0001) 
-0.29 
(<.0001) 
0.42 
(<.0001) 
-0.12 
 (.01) 
0.007  
(.44) 
HMW-adiponectin  1.00 0.68 (<.0001) 
0.28 
(<.0001) 
-0.12 
(<.0001) 
-0.10 
(.002) 
-0.17 
(<.0001) 
-0.28 
(<.0001) 
0.40 
(<.0001) 
-0.11 
(<.0001) 
0.03 
(.31) 
Non-HMW adiponectin   1.00 0.28 (<.0001) 
-0.15 
(<.0001) 
-0.09 
(.01) 
-0.19 
(<.0001) 
-0.25 
(<.0001) 
0.35 
(<.0001) 
-0.10 
 (.001) 
-0.02 
 (.31) 
sOB-R  
   1.00 
-0.19 
(<.0001) 
-0.10 
(<.0001) 
-0.31 
(<.0001) 
-0.24 
(<.0001) 
0.26 
(<.0001) 
-0.11 
(<.0001) 
-0.02  
(.49) 
CRP-hs  
    1.00 
0.16 
(.0003) 
0.18 
(<.0001) 
0.15 
(<.0001) 
-0.15 
(<.0001) 
-0.17 
(<.0001) 
0.42 
 (<.0001) 
HbA1c   
     1.00 
0.16 
(<.0001) 
0.15 
(.0001) 
-0.10 
(.01) 
-0.01  
(.28) 
0.17 
 (<.0001) 
C-peptide  
      1.00 
0.34 
(<.0001) 
-0.20 
(<.0001) 
0.07  
(.53) 
0.10 
 (.001) 
HDL-cholesterol        1.00 -0.39 (<.0001) 
-0.05 
 (.43) 
0.16 
 (<.0001) 
Triglycerides  
        1.00 
-0.02 
 (.44) 
-0.01  
(.57) 
IGF-1  
         1.00 
-0.13  
(.0001) 
ROM           1.00 
 
 
aP-value for trend (two sided) across tertiles is based on the median biomarker concentrations within tertiles as a continuous variable. Wald χ2 test was employed to evaluate the 
significance of the linear trend.  
bCrude model is taking into account matching factors: age, sex, study centre, follow-up time since blood collection, time of the day at blood collection and fasting status; Women 
were further matched by menopausal status, phase of menstrual cycle at blood collection and postmenopausal women were matched by HRT use.  
cMultivariable model was based on the crude model with additional adjustment for smoking status (never, past, current, or unknown), education (no school degree or primary 
school, technical or professional school, secondary school, university degree, or unknown), alcohol intake (continuous), and physical activity (inactive, moderately inactive, 
moderately active, active, or missing).  
WC = waist circumference; HbA1c; = glycated hemoglobin; HDL-cholesterol =high-density-lipoprotein cholesterol; CRP-hs = high-sensitivity C-reactive protein; ROM = reactive 
oxygen metabolites; HMW-adiponectin = high-molecular-weight adiponectin; sOB-R = soluble leptin receptor; T = tertile; Ptrend=P for trend across tertiles; All P values are two-
sided. 
 
Table 4 Relative risks (95% confidence intervals) of colon cancer by tertiles of  waist circumference before and after adjustment for biomarkers in men and women, the 
European Prospective Investigation into Cancer and Nutrition  Cohort (1992-2003) 
 Men Women 
Tertiles T1 T2 T3 
Ptrenda 
T1 T2 T3 
Ptrenda Median WC (cm) 86.6 95.0 104.7 71.7 80.4 93.0 
n, cases /controls 83/102 82/100 127/90 103/122 121/119 146/129 
Crude modelb Referent 1.03 (0.66 - 1.61) 1.82 (1.19 - 2.78) 0.0001 Referent 1.24 (0.85 - 1.82) 1.43 (0.97 - 2.12) 0.08 
Multivariable modelc Referent 0.92 (0.57 - 1.40) 1.68 (1.06 - 2.65) 0.02 Referent 1.36 (0.91 - 2.03) 1.67 (1.09 - 2.56) 0.03 
Further adjustment for           
Adiponectin Referent  0.83 (0.56 - 1.46) 1.49 (0.92 - 2.42) 0.05 Referent 1.33 (0.89 - 2.00) 1.61 (1.03 - 2.53) 0.05 
HMW-adiponectin Referent  0.86 (0.53 - 1.41) 1.56 (0.97 - 2.52) 0.03 Referent 1.42 (0.94 - 2.15) 1.81 (1.15 - 2.84) 0.02 
non HMW-adiponectin Referent  0.81 (0.49 - 1.32) 1.44 (0.89 - 2.33) 0.07 Referent 1.26 (0.83 - 1.89) 1.43 (0.91 - 2.23) 0.15 
sOB -R Referent  0.79 (0.48 - 1.29) 1.32 (0.81 - 2.15) 0.17 Referent 1.25 (0.83 - 1.89) 1.42 (0.91 - 2.25) 0.15 
CRP-hs Referent  0.91 (0.57 - 1.46) 1.63 (1.02 - 2.59) 0.03 Referent 1.36 (0.91 - 2.03) 1.65 (1.07 - 2.53) 0.03 
HbA1c Referent  0.89 (0.55 - 1.43) 1.60 (1.00 - 2.56) 0.03 Referent 1.36 (0.91 - 2.04) 1.62 (1.04 - 2.53) 0.04 
C-peptide Referent  0.94 (0.58 - 1.51) 1.75 (1.08 - 2.80) 0.01 Referent 1.33 (0.89 - 2.00) 1.57 (0.98 - 2.49) 0.07 
HDL-cholesterol Referent  0.82 (0.50 - 1.33) 1.46 (0.91 - 2.35) 0.06 Referent 1.29 (0.86 - 1.94) 1.51 (0.97 - 2.37) 0.08 
Triglycerides Referent  0.91 (0.57 - 1.47) 1.64 (1.03 - 2.64) 0.02 Referent 1.35 (0.90 - 2.02) 1.68 (1.04 - 2.56) 0.04 
ROM Referent  0.92 (0.57 - 1.49) 1.49 (0.93 - 2.39) 0.07 Referent 1.39 (0.93 - 2.09) 1.62 (1.05 - 2.49) 0.04 
 
 
aMultivariable model was taking into account matching factors: age, sex, study centre, follow-up time since blood collection, time of the day at blood collection and fasting status; 
Women were further matched by menopausal status, phase of menstrual cycle at blood collection and postmenopausal women were matched by HRT use; with additional 
adjustment for smoking status (never, past, current, or unknown), education (no school degree or primary school, technical or professional school, secondary school, university 
degree, or unknown), alcohol intake (continuous), and physical activity (inactive, moderately inactive, moderately active, active, or missing). 
bThe β-coefficient (regression coefficient) is the natural  log of the RR estimate.  
cThe percent change in the regression coefficient with adjustment for each additional biomarker compared with the multivariable model.  
dThe corresponding 95% confidence interval (CI) was calculated based on Fieller’s theorem 24.  
RR= relative risk; CI = confidence interval; HbA1c = glycated hemoglobin; IGF-1= insulin growth factor 1; HDL-cholesterol = high-density-lipoprotein cholesterol; CRP-hs = 
high sensitivity C-reactive protein; ROM = reactive oxygen metabolites; HMW-adiponectin = high-molecular-weight adiponectin; sOB-R= soluble leptin receptor. 
Table 5 Relative risks, 95 % confidence intervals and regression coefficients for risk of colon cancer associated with waist circumference (continuously per 10 cm 
increase) and percent change in regression coefficients with adjustment for each additional biomarker, the European Prospective Investigation into Cancer and Nutrition  
Cohort (1992-2003) 
 Men Women 
 RR (95%CI) βb % changec 95% CId RR (95%CI) βb % changec 95% CId 
n, cases /controls 292/292 370/370 
Multivariable modela 1.33 (1.26 - 1.41) 0.29   1.20 (1.14 - 1.25) 0.18   
Further adjustment for         
Adiponectin 1.29 (1.22 - 1.37) 0.26 11 7 to 16 1.18 (1.12 - 1.24) 0.17 6 1 to 11 
HMW-adiponectin 1.31 (1.24 - 1.39) 0.27 6  2 to 9 1.22 (1.16 - 1.28) 0.20 -12 -19 to -6 
Non-HMW-adiponectin 1.27 (1.20 - 1.35) 0.24 16 11 to 21 1.14 (1.08 - 1.19) 0.13 28 20 to 36 
sOB-R 1.21 (1.14 - 1.29) 0.19 33 25 to 42 1.14 (1.09 - 1.19) 0.13 28 20 to 38 
CRP-hs 1.31 (1.24 - 1.39) 0.27 6 2 to 9 1.19 (1.14 - 1.25) 0.18 2 -1 to 5 
HbA1c 1.31 (1.24 - 1.39) 0.27 6 2 to 9 1.18 (1.13 - 1.24) 0.17 4 -1 to 8 
C-peptide 1.37 (1.29 - 1.45) 0.31 -9 -14 to -4 1.13 (1.12 - 1.23) 0.16 30 22 to 40 
HDL-cholesterol 1.26 (1.19 - 1.34) 0.23 19 14 to 25 1.16 (1.11 - 1.22) 0.15 16 11 to 22 
Triglycerides 1.34 (1.26 - 1.42) 0.29 0.05 - 1.19 (1.14 - 1.25) 0.17 4 -2 to 9 
ROM 1.26 (1.19 - 1.33) 0.23 21 16 to 26 1.18 (1.13 - 1.24) 0.17 8 9 to 12 
sOB-R+non-HMW adiponectin+HDL-cholesterol 1.17 (1.09 - 1.24) 0.16 46 37 to 57 1.09 (1.04 - 1.15) 0.09 50 40 to 65 
sOB-R+non-HMW adiponectin+HDL-C+ROM 1.08 (1.01 - 1.16) 0.08 71 58 to 86 1.08 (1.03 - 1.13) 0.07 58 47 to 75 
sOB-R+non-HMW adiponectin+HDL-C+C-peptide 1.21 (1.14 - 1.29) 0.19 33 24 to 44 1.09 (1.09 - 1.15) 0.09 53 40 to 68 
